USA: Pharma Deal Eli Lilly to Take Over TVM Capital Life Science’s ‘Aurka Pharma’

Editor: Ahlam Rais

The acquisition will enable Lilly to expand its pipeline with promising oncology compounds. The firm is hoping to deliver a potential new medicine for tumour patients via this deal.

Related Vendors

The acquisition of Aurka Pharma expands the firm’s pipeline with a promising oncology compound targeting a distinct cell cycle pathway.
The acquisition of Aurka Pharma expands the firm’s pipeline with a promising oncology compound targeting a distinct cell cycle pathway.
(Source: Deposit Photos)

Indiana/USA – Eli Lilly and Company have recently announced an agreement to acquire Aurka Pharma, a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that Aurka Pharma is studying in Phase 1 clinical trials in multiple types of solid tumours.

After a review of its clinical pipeline priorities in 2016, Lilly sold the compound to TVM Capital Life Science, which then established Aurka as part of the TVM Life Science Ventures VII fund. The fund is a novel investment model that seeks to develop early-stage pharmaceutical assets in a capital-efficient manner. As part of its innovation strategy, Lilly actively participates with venture capital firms to source early stage opportunities.

The acquisition of Aurka Pharma expands the firm’s pipeline with a promising oncology compound targeting a distinct cell cycle pathway. Through the unique healthcare venture capital model pioneered by TVM Capital Life Science, companies such as Aurka have been established to more quickly and efficiently bring promising compounds to clinical proof-of-concept.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:45316269)